Coloplast (CPSE:COLO B) - Cours de l'action, nouvelles et analyse

COLO B Aperçu des actions

Coloplast A/S développe et vend des produits et des services de soins intimes au Danemark, aux États-Unis, au Royaume-Uni, en France et dans le monde entier. Plus de détails

COLO B analyse fondamentale
Score flocon de neige
Évaluation	3/6
Croissance future	3/6
Performances passées	3/6
Santé financière	2/6
Dividendes	3/6

Récompenses

Se négocie à 41.1% en dessous de notre estimation de sa juste valeur

Les bénéfices devraient augmenter 12.85% par an

Les revenus ont augmenté 4.9% par an au cours des 5 dernières années

Analyse des risques

La dette n’est pas bien couverte par le flux de trésorerie opérationnel

Le dividende de 2.47% n'est pas bien couvert par les bénéfices ou les flux de trésorerie disponibles

Coloplast A/S Concurrents

Demant

CPSE:DEMANT

DKK 57.6b

Ambu

CPSE:AMBU B

DKK 31.7b

Embla Medical hf

CPSE:EMBLA

DKK 15.1b

Cooper Companies

NasdaqGS:COO

US$19.8b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Coloplast
Historique des cours de bourse
Prix actuel de l'action	DKK 890.00
Plus haut sur 52 semaines	DKK 977.60
Plus bas sur 52 semaines	DKK 739.60
Bêta	0.34
1Variation sur 1 mois	-0.71%
Variation sur 3 mois	0.25%
Variation sur 1 an	18.32%
3Variation sur 3 ans	-24.67%
Variation sur 5 ans	11.33%
Évolution depuis l'introduction en bourse	6,865.22%

Nouvelles et mises à jour récentes

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 13

Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Nov 08

Recent updates

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 13

Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Nov 08

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Oct 18

Coloplast A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 23

Are Investors Undervaluing Coloplast A/S (CPH:COLO B) By 38%?

Aug 22

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

Jul 17

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jun 29

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

May 21

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

May 10

Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

May 09

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 04

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Nov 16

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Sep 30

Is Coloplast (CPH:COLO B) A Risky Investment?

Jun 28

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Jun 10

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Mar 22

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

Mar 01

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 14

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 26

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Nov 25

Coloplast's (CPH:COLO B) Shareholders Will Receive A Bigger Dividend Than Last Year

Nov 11

With EPS Growth And More, Coloplast (CPH:COLO B) Makes An Interesting Case

Oct 25

Estimating The Fair Value Of Coloplast A/S (CPH:COLO B)

Aug 26

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jul 27

Here's Why We Think Coloplast (CPH:COLO B) Is Well Worth Watching

Jul 12

Is There An Opportunity With Coloplast A/S' (CPH:COLO B) 45% Undervaluation?

May 23

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of kr.5.00

May 08

Rendement pour les actionnaires

	COLO B	DK Medical Equipment	DK Marché
7D	-4.2%	-1.2%	-3.1%
1Y	18.3%	16.5%	5.7%

Rendement vs Industrie: COLO B a dépassé le secteur Danish Medical Equipment qui a rapporté 16.5 % au cours de l'année écoulée.

Rendement vs marché: COLO B a dépassé le marché Danish qui a rapporté 5.7 % au cours de l'année écoulée.

Volatilité des prix

Is COLO B's price volatile compared to industry and market?
COLO B volatility
COLO B Average Weekly Movement	3.7%
Medical Equipment Industry Average Movement	3.7%
Market Average Movement	4.2%
10% most volatile stocks in DK Market	10.5%
10% least volatile stocks in DK Market	2.4%

Cours de l'action stable: COLO B n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de COLO B ( 4% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1954	16,639	Kristian Villumsen	www.coloplast.com

Coloplast A/S développe et vend des produits et des services de soins intimes au Danemark, aux États-Unis, au Royaume-Uni, en France et dans le monde entier. La société opère à travers les segments Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, et Advanced Wound Care. Elle fournit des produits de soins pour stomies, notamment SenSura Mio, qui s'adapte aux formes corporelles individuelles et offre une discrétion optimale pour divers types de stomies, et SenSura Ostomy care solutions, ainsi que des accessoires pour stomies sous la marque Brava.

Coloplast A/S Résumé des fondamentaux

Comment les bénéfices et les revenus de Coloplast se comparent-ils à sa capitalisation boursière ?
COLO B statistiques fondamentales
Capitalisation boursière	DKK 202.89b
Bénéfices(TTM)	DKK 5.05b
Recettes(TTM)	DKK 27.03b

39.7x

Ratio P/E

7.4x

Ratio P/S

Le site COLO B est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
COLO B compte de résultat (TTM)
Recettes	DKK 27.03b
Coût des recettes	DKK 8.76b
Marge brute	DKK 18.27b
Autres dépenses	DKK 13.22b
Les revenus	DKK 5.05b

Derniers bénéfices déclarés

Sep 30, 2024

Prochaine date de publication des résultats

Feb 04, 2025

Résultat par action (EPS)	22.44
Marge brute	67.59%
Marge bénéficiaire nette	18.69%
Ratio dettes/capitaux propres	120.6%

Quelles ont été les performances à long terme de COLO B?

Voir les performances historiques et les comparaisons

Dividendes

2.5%

Rendement actuel des dividendes

98%

Ratio de distribution

Le site COLO B verse-t-il des dividendes fiables ?

Voir COLO B l'historique des dividendes et les indices de référence

Quand faut-il acheter COLO B pour recevoir un dividende à venir ?
Coloplast dates des dividendes
Date ex-dividende	Dec 06 2024
Date de paiement du dividende	Dec 10 2024
Jours jusqu'au dividende Ex	17 days
Jours jusqu'à la date de paiement du dividende	21 days

Le site COLO B verse-t-il des dividendes fiables ?

Voir COLO B l'historique des dividendes et les indices de référence

COLO B Aperçu des actions

Récompenses

Analyse des risques

Coloplast A/S Concurrents

CPSE:DEMANT

DKK 57.6b

CPSE:AMBU B

DKK 31.7b

CPSE:EMBLA

DKK 15.1b

NasdaqGS:COO

US$19.8b

Historique des prix et performances

Nouvelles et mises à jour récentes

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Final dividend increased to kr.17.00

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Final dividend increased to kr.17.00

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

President & CEO exercised options and sold kr.5.0m worth of stock

Executive Vice President of Growth exercised options to buy kr.28m worth of stock.

Coloplast A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Are Investors Undervaluing Coloplast A/S (CPH:COLO B) By 38%?

Third quarter 2024 earnings: EPS misses analyst expectations

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

First half dividend of kr.5.00 announced

Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

Second quarter 2024 earnings: EPS misses analyst expectations

A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)

There's Reason For Concern Over Coloplast A/S' (CPH:COLO B) Price

Is Coloplast (CPH:COLO B) A Risky Investment?

President & CEO exercised options and sold kr.13m worth of stock

First quarter 2024 earnings: Revenues in line with analyst expectations

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Estimating The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S' (CPH:COLO B) Price Is Out Of Tune With Earnings

Coloplast A/S Approves the Distribution of Year-End Dividend

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Now 20% undervalued after recent price drop

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Deputy Chairman recently bought kr.40m worth of stock

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

New minor risk - Shareholder dilution

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Is Coloplast (CPH:COLO B) A Risky Investment?

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

First quarter 2023 earnings: EPS misses analyst expectations

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Upcoming dividend of kr.15.00 per share

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Less than half of directors are independent